Alpha-Maven Cannabis Investment Dashboard:

Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

3d ago Cannabis greenmarketreport Views: 42

Entourage Health Corp.(formerly WeedMD Inc.) (TSX-V:ENTG)(OTCQX:WDDMF) announced preliminary unaudited revenues of $13.6 million for the three months ending June 30, 2021. The company said this was another sequential quarter of record sales growth across its adult-use and medical sales channels. “The launch of our expanded portfolio of products, increased retail sales presence and distribution across Canada – combined with further developments in our medical sales platform – resulted in sequential quarter growth and a meaningful increase in our Q2 revenue,” said George Scorsis, Interim CEO and Executive Chairman. “Our continued transformation initiatives, cost improvements and steadily growing consumer demand for our top-selling Color Cannabis and Saturday Cannabis dried flower, pre-rolls, vapes, live resin, and multi-pack products have positioned us well for further growth. With the expected addition of craft brandRoyal City Cannabisto our portfolio, we’re looking forward to expanding our consumer offerings and bringing additional value to our shareholders.” Entourage owns and operates a 158-acre state-of-the-art greenhouse, outdoor, and processing facility located in Strathroy, ON as well as a fully licensed 26,000 sq. ft. Aylmer, ON processing facility, specializing in cannabis extraction. Name Change Entourage recently changed its name from “WeedMD Inc.” to “Entourage Health Corp.” Its common shares will continue to be publicly traded on the TSX Venture Exchange under the new ticker symbol “ENTG”, with a new CUSIP number of 293861100 and ISIN number of CA2938611001. These changes took place on July 16. In connection with the name change, the company also confirmed its convertible debentures maturing September 25, 2022, Common Share purchase warrants expiring September 25, 2022 and Common Share purchase warrants expiring March 12, 2023 and their respective ticker symbols “ENTG.DB”, “ENTG.WT”, and “ENTG.WT.A”, also began trading on July 16. Entourage said it plans to file its second-quarter 2021 financial statements and management’s discussion and analysis pre-market on Tuesday, August 10, 2021. Entourage will host a conference call the same day at 10 a.m. Eastern Time to review the results, provide an operational update and discuss recent milestones. Entourage Reports $13 Million In Second Quarter Revenue on Green Market Report. -

Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.